Biosimilars

Choosing a biosimilar

Biosimilars have been approved for use in Canada since 2009³, and there are currently 40⁴, or more biosimilars approved or marketed in Canada. All biosimilar manufacturers must independently demonstrate the quality of their product and perform comparative studies to demonstrate highly similar structure, function, efficacy and safety to the reference biologic.³

At Fresenius-Kabi we uphold the same quality standards in developing and producing biosimilars as the originator biologics.

Benefits of biosimilar medicines

Biosimilars facilitate patient access, provide more affordable treatment options, and encourage innovation.^1,2

Lower cost

The development of biosimilars can create lower patient costs for treatment, which can lead to:

Increased uptake of best-value biologics^1,2
Reinvestment of cost savings in the development of new and innovative therapies¹
Improved patient care¹
Additional treatment choices for patients and HCPs¹

Encouraging innovation

The development of biosimilars can create a more progressive, competitive environment, encouraging investment in the development of new biologic products.¹

This can lead to:

Innovation among reference product manufacturers¹
Increased uptake of best-value biologics^1,2
Reinvestment of cost savings in the development of new and innovative therapies¹

More information about our commitment to biosimilars and the biosimilars we have in development.

References:
1. IMS Institute 2016. Delivering on the potential of biosimilar medicines. p. 3, 6, 8, 10, 29 at: www.medicinesforeurope.com.
2. IMS Health 2016. The impact of biosimilar competition, p. 4, 6 and 7. at: www.medicinesforeurope.com.
3.Health Canada. Biosimilar biologic drugs in Canada: fact sheet. 2019
4.Canadian Biologics Market report for Q2 – 2022